ClinicalTrials.gg
TerminatedNCT04155424Updated Sep 25, 2024Results posted

A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder

A Phase 2/3 interventional study of Eculizumab in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder, sponsored by Alexion Pharmaceuticals, Inc.. Terminated at 35 sites in 7 countries. Per ClinicalTrials.gov, last updated 2024-09-25.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 2/3, Interventional, and Treatment

Why this study was terminated
Pediatric clinical study is not feasible.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
5
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Neuromyelitis Optica by AstraZeneca — 3 open to participants now, 5 under way, 3 of them phase 3. Neuromyelitis Optica · AstraZeneca.

Started
2020
the only one that year
Phase 2/3
3 of 11
none open now
Registered
4th of 11
by date

Among the 11 studies in Neuromyelitis Optica by AstraZeneca, this one is the only one that started in 2020, is one of 3 in phase 2/3, and was the 4th registered.

Neuromyelitis Optica

178 studies on the registry are indexed under Neuromyelitis Optica; 78 are open to participants now.

Browse Neuromyelitis Optica studies →

Open to participants now

3 of the 11 studies in Neuromyelitis Optica by AstraZeneca are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 50 Neuromyelitis Optica studies recruiting now, 29 (58%) set no upper age limit and 16 (32%) stop at 75 or younger; 11 take children under 18; 9 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Neuromyelitis Optica by AstraZeneca, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the safety and efficacy of eculizumab in pediatric participants (aged 2 to \< 18 years) with relapsing neuromyelitis optica spectrum disorder (NMOSD).

03

Conditions studied

  • Neuromyelitis Optica
  • Neuromyelitis Optica Spectrum Disorder

Keywords

  • Neuromyelitis Optica
  • Neuromyelitis Optica Spectrum Disorder
  • Devic's Disease
  • Transverse Myelitis
  • Optic Neuritis
  • Relapse
  • Eculizumab
  • Soliris
  • CNS Autoimmune Disorders
  • Demyelinating Disorders
  • NMO
  • NMOSD
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants aged 2 years to \< 18 years with body weight ≥ 10 kilograms (kg).
  2. Vaccinated against Neisseria meningitidis within 3 years prior to, or at the time of initiating eculizumab. Participants who initiate study drug treatment less than 2 weeks after receiving a meningococcal vaccine must receive appropriate prophylactic antibiotics until 2 weeks after the vaccination.
  3. Documented vaccination against haemophilus influenzae type b and streptococcus pneumoniae infections at least 2 weeks prior to dosing as per local and country-specific immunization guidelines for the appropriate age group.
  4. Anti-aquaporin-4 antibody-positive and diagnosis of NMOSD as defined by the 2015 International Panel for Neuromyelitis Optica Diagnosis criteria.
  5. Historical Relapse Rate of at least 2 relapses in the last 2 years, and with at least 1 relapse in the year prior to Screening.
  6. EDSS score ≤ 7.
  7. Participants who enter the study receiving supportive therapies (ISTs) for the prevention of relapse, either in combination or monotherapy, must be on a stable dosing regimen of adequate duration.
  8. Female participants of must have a negative pregnancy test (serum human chorionic gonadotropin) at Screening and follow protocol-specified guidance for avoiding pregnancy while on treatment and for 5 months after the last dose of eculizumab.
  9. Male participants with a female spouse/partner of childbearing potential or a pregnant or breastfeeding spouse or partner must agree to use double barrier contraception (male condom plus appropriate barrier method for the female partner) while on treatment and for at least 5 months after the last dose of eculizumab.

Exclusion criteria

Exclusion Criteria:

  1. Parent or legal guardian is an Alexion employee.
  2. Pregnant, breastfeeding, or intending to conceive during the course of the study.
  3. Participants known to be positive or with congenital immunodeficiency.
  4. Unresolved meningococcal or other serious infection.
  5. Any unresolved acute or chronic systemic bacterial or other infection that is in the opinion of the Investigator and has not been treated with appropriate antibiotics.
  6. Use of rituximab or other biologicals such as tocilizumab within 6 months prior to Screening.
  7. Use of mitoxantrone within 3 months prior to Screening.
  8. Use of intravenous immunoglobulin or plasma exchange within 3 weeks prior to Screening.
  9. Use of immunomodulatory therapies for multiple sclerosis within 3 months prior to Screening.
  10. Has previously received treatment with eculizumab or other complement inhibitors.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Eculizumab

    All participants will receive open-label eculizumab by intravenous infusion during the Primary Treatment Period, starting on Day 1 and for a total of 52/53 weeks. The dosing regimen will be based on the participant's body weight. As body weight changes during the study, the participant's weight cohort and dose may change accordingly. After completing the 52/53-week Primary Treatment Period, participants may continue receiving eculizumab in the Extension Treatment Period for 104 weeks.

    Drug: Eculizumab

Interventions

  • Following a weight-based weekly dose of eculizumab during an induction phase, participants will receive weight-based doses of eculizumab every 2 weeks during the Primary Treatment Period and Extension Treatment Period.

    Also known as: Soliris

06

What researchers measure

Primary outcomes

  1. Change Between the Baseline Annualized Relapse Rate (ARR) and the On-Trial ARR at Week 52/53

    ARR was calculated as the number of relapses for each participant divided by the number of years of treatment for that participant. Baseline ARR was based on 24 months prior to screening.

    Time frame: Baseline, Week 52/53

  2. Time to First On-trial Relapse

    Time to First Relapse was defined as beginning at the time the participant's first dose of eculizumab was administered until the participant's first on-trial relapse was reported by the Investigator. Participants who did not experience an on-trial relapse were censored at the end of the study period.

    Time frame: Baseline up to Week 52/53

Secondary outcomes

  1. Change From Baseline in Expanded Disability Status Scale (EDSS) Score at Week 52/53

    Disease-related disability was measured by the EDSS. The EDSS is an ordinal clinical rating scale that ranges from 0 (normal neurologic examination) to 10 (death) in half-point increments. A decrease in score indicates improvement.

    Time frame: Baseline, Week 52/53

  2. Change From Baseline in the Hauser Ambulation Index (HAI) Score at Week 52/53

    The HAI evaluates gait and was used to assess the time and effort used by the participant to walk 25 feet (8 meters). The scale ranged from 0 to 9, with 0 being the best score (asymptomatic; fully ambulatory with no assistance) and 9 being the worst (restricted to wheel chair; unable to transfer self independently). A decrease in score indicates improvement.

    Time frame: Baseline, Weeks 52/53

  3. Change From Baseline in Pediatric Quality of Life Inventory (PedsQL) Score at Week 52/53

    PedsQL included a child self-report for participants 5 to 18 years with a 23-item PedsQL Generic Core Scales report. The PedsQL Generic Core Scales report included 4 scales, physical functioning, emotional functioning, social functioning, and school functioning. Each item used a 5-point rating scale (from 0=never to 4=almost always). Items are reverse scored and linearly transformed to a 0 (almost always) -100 (never) scale. All summary/total scores were mean of specific items where higher score indicated better HRQoL.

    Time frame: Baseline, Weeks 52/53

  4. Number of Participants With Shift From Baseline in Visual Acuity (VA)

    The Snellen chart was used to assess VA. The Snellen chart quantifies ability to read letters of varying sizes at a fixed distance in relation to the distance at which a participant with normal vision could read the same letters. The test was performed at a standard distance, typically 6 meters or 20 feet. The Snellen chart is typically recorded as acuity ratio distance (6 meters or 20 feet), so for normal VA it would be recorded as 20/20 or 6/6. Visual acuity was summarized according to the eye with greater worsening at the end of primary treatment period (Week 52/53). Data are presented for number of participants with a shift from baseline in VA presented per the different levels of acuity ratio distance. Baseline was defined as the last available assessment prior to the first IP study drug infusion for all participants regardless of treatment group. Visual Acuity data are only reported for the categories with available data at Baseline and Week 52/53.

    Time frame: Baseline, Week 52/53

  5. Number of Participants With Shift From Baseline in Confrontational Visual Fields (VF)

    Confrontational visual fields were summarized according to the number of quadrants with deficits across both eyes. Baseline was defined as the last available assessment prior to the first IP study drug infusion for all participants regardless of treatment group.

    Time frame: Baseline, Weeks 52/53

  6. Number of Participants With Shift From Baseline in Color Vision

    Color vision was evaluated as the shift from baseline and described for participants with normal color vision at baseline in at least one eye. Participants with 13 or less correctly identified Ishihara plates were considered as having abnormal color vision, participants with 14 or more correctly identified plates were considered as having normal color vision. Baseline was defined as the last available assessment prior to the first IP study drug infusion for all participants regardless of treatment group.

    Time frame: Baseline, Weeks 52/53

  7. Serum Eculizumab Concentration at Week 52

    Time frame: Week 52

  8. Change From Baseline in Serum Free Complement Protein 5 (C5) Concentrations at Week 52

    Time frame: Baseline, Week 52

07

Results

Posted Sep 25, 2024
Limitations and caveats
The study was terminated by Alexion, as only 5 of the planned 12 participants were enrolled due to difficulty in recruitment.

Participant flow

Participant flow — Overall Study
MilestoneEculizumab
Started5
Received at least 1 dose of study drug5
Number of participants who received study drug during the induction period5
Number of participants who received study drug during the maintenance period5
Completed0
Not completed5
Withdrew: Other than specified3
Withdrew: Withdrawal by subject1
Withdrew: Adverse event1

Outcome measures

PrimaryChange Between the Baseline Annualized Relapse Rate (ARR) and the On-Trial ARR at Week 52/53

ARR was calculated as the number of relapses for each participant divided by the number of years of treatment for that participant. Baseline ARR was based on 24 months prior to screening.

Time frame:
Baseline, Week 52/53
Reported as:
Mean · relapses per participant per year
Change Between the Baseline Annualized Relapse Rate (ARR) and the On-Trial ARR at Week 52/53
relapses per participant per yearEculizumab
Change Between the Baseline Annualized Relapse Rate (ARR) and the On-Trial ARR at Week 52/53-3.01 ± 2.504
PrimaryTime to First On-trial Relapse

Time to First Relapse was defined as beginning at the time the participant's first dose of eculizumab was administered until the participant's first on-trial relapse was reported by the Investigator. Participants who did not experience an on-trial relapse were censored at the end of the study period.

Time frame:
Baseline up to Week 52/53

No measurements were reported for this outcome.

SecondaryChange From Baseline in Expanded Disability Status Scale (EDSS) Score at Week 52/53

Disease-related disability was measured by the EDSS. The EDSS is an ordinal clinical rating scale that ranges from 0 (normal neurologic examination) to 10 (death) in half-point increments. A decrease in score indicates improvement.

Time frame:
Baseline, Week 52/53
Reported as:
Mean · score on a scale
Change From Baseline in Expanded Disability Status Scale (EDSS) Score at Week 52/53
score on a scaleEculizumab
Change From Baseline in Expanded Disability Status Scale (EDSS) Score at Week 52/53-0.75 ± 1.708
SecondaryChange From Baseline in the Hauser Ambulation Index (HAI) Score at Week 52/53

The HAI evaluates gait and was used to assess the time and effort used by the participant to walk 25 feet (8 meters). The scale ranged from 0 to 9, with 0 being the best score (asymptomatic; fully ambulatory with no assistance) and 9 being the worst (restricted to wheel chair; unable to transfer self independently). A decrease in score indicates improvement.

Time frame:
Baseline, Weeks 52/53
Reported as:
Mean · score on a scale
Change From Baseline in the Hauser Ambulation Index (HAI) Score at Week 52/53
score on a scaleEculizumab
Change From Baseline in the Hauser Ambulation Index (HAI) Score at Week 52/530.0 ± 0.00
SecondaryChange From Baseline in Pediatric Quality of Life Inventory (PedsQL) Score at Week 52/53

PedsQL included a child self-report for participants 5 to 18 years with a 23-item PedsQL Generic Core Scales report. The PedsQL Generic Core Scales report included 4 scales, physical functioning, emotional functioning, social functioning, and school functioning. Each item used a 5-point rating scale (from 0=never to 4=almost always). Items are reverse scored and linearly transformed to a 0 (almost always) -100 (never) scale. All summary/total scores were mean of specific items where higher score indicated better HRQoL.

Time frame:
Baseline, Weeks 52/53
Reported as:
Mean · score on a scale
Change From Baseline in Pediatric Quality of Life Inventory (PedsQL) Score at Week 52/53
score on a scaleEculizumab
Change From Baseline in Pediatric Quality of Life Inventory (PedsQL) Score at Week 52/53-5.01 ± 10.401
SecondaryNumber of Participants With Shift From Baseline in Visual Acuity (VA)

The Snellen chart was used to assess VA. The Snellen chart quantifies ability to read letters of varying sizes at a fixed distance in relation to the distance at which a participant with normal vision could read the same letters. The test was performed at a standard distance, typically 6 meters or 20 feet. The Snellen chart is typically recorded as acuity ratio distance (6 meters or 20 feet), so for normal VA it would be recorded as 20/20 or 6/6. Visual acuity was summarized according to the eye with greater worsening at the end of primary treatment period (Week 52/53). Data are presented for number of participants with a shift from baseline in VA presented per the different levels of acuity ratio distance. Baseline was defined as the last available assessment prior to the first IP study drug infusion for all participants regardless of treatment group. Visual Acuity data are only reported for the categories with available data at Baseline and Week 52/53.

Time frame:
Baseline, Week 52/53
Reported as:
Count of participants · Participants
Number of Participants With Shift From Baseline in Visual Acuity (VA)
ParticipantsEculizumab
Shift from VA 20/20-20/29 to VA 20/20-20/293
Shift from VA 20/30-20/59 to VA 20/20-20/291
SecondaryNumber of Participants With Shift From Baseline in Confrontational Visual Fields (VF)

Confrontational visual fields were summarized according to the number of quadrants with deficits across both eyes. Baseline was defined as the last available assessment prior to the first IP study drug infusion for all participants regardless of treatment group.

Time frame:
Baseline, Weeks 52/53
Reported as:
Count of participants · Participants
Number of Participants With Shift From Baseline in Confrontational Visual Fields (VF)
ParticipantsEculizumab
0 to 02
2 to 01
SecondaryNumber of Participants With Shift From Baseline in Color Vision

Color vision was evaluated as the shift from baseline and described for participants with normal color vision at baseline in at least one eye. Participants with 13 or less correctly identified Ishihara plates were considered as having abnormal color vision, participants with 14 or more correctly identified plates were considered as having normal color vision. Baseline was defined as the last available assessment prior to the first IP study drug infusion for all participants regardless of treatment group.

Time frame:
Baseline, Weeks 52/53
Reported as:
Count of participants · Participants
Number of Participants With Shift From Baseline in Color Vision
ParticipantsEculizumab
No Change from Normal4
Worsened from Baseline0
SecondarySerum Eculizumab Concentration at Week 52
Time frame:
Week 52
Reported as:
Mean · micrograms/milliliters
Serum Eculizumab Concentration at Week 52
micrograms/millilitersEculizumab
Pre-dose: 5-90 Minutes460.7 ± 65.04
Post-dose: 60 minutes971.3 ± 198.04
SecondaryChange From Baseline in Serum Free Complement Protein 5 (C5) Concentrations at Week 52
Time frame:
Baseline, Week 52
Reported as:
Mean · micrograms/milliliters
Change From Baseline in Serum Free Complement Protein 5 (C5) Concentrations at Week 52
micrograms/millilitersEculizumab
Baseline166.67 ± 50.203
Change from Baseline at Week 52-166.64 ± 50.194

Adverse events

Collected over Baseline up to Week 53. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eculizumab0/5 (0%)2/5 (40%)5/5 (100%)
Most frequent serious events
Most frequent serious events
EventEculizumab
Liver function test increasedInvestigations1/5
Encephalitis meningococcalInfections and infestations1/5
Most frequent other events
Showing 10 of 35
Most frequent other events
EventEculizumab
Pain in extremityMusculoskeletal and connective tissue disorders2/5
AmenorrhoeaReproductive system and breast disorders1/4
Abdominal pain lowerGastrointestinal disorders1/5
Bowel movement irregularityGastrointestinal disorders1/5
ConstipationGastrointestinal disorders1/5
Dental cariesGastrointestinal disorders1/5
NauseaGastrointestinal disorders1/5
VomitingGastrointestinal disorders1/5
Feeling abnormalGeneral disorders1/5
PyrexiaGeneral disorders1/5

Baseline characteristics

Safety Set included all participants who received at least 1 dose of eculizumab.

Age, Continuous
Age, Continuous(years)Eculizumab
Mean12.0 ± 4.36
Sex: Female, Male
Sex: Female, Male(Participants)Eculizumab
Female4
Male1
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Eculizumab
Hispanic or Latino2
Not Hispanic or Latino3
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Eculizumab
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American1
White2
More than one race0
Unknown or Not Reported1
08

Study locations

35 sites
  • Clinical Trial Site
    San Francisco, California 94016, United States
  • Clinical Trial Site
    Washington, District of Columbia 20001, United States
  • Clinical Trial Site
    Miami, Florida 33101, United States
  • Clinical Trial Site
    Atlanta, Georgia 30301, United States
  • Research Site
    Baltimore, Maryland 21287, United States
  • Clinical Trial Site
    Rockville, Maryland 20847, United States
  • Clinical Trial Site
    Boston, Massachusetts 02101, United States
  • Research Site
    Boston, Massachusetts 02115, United States
  • Research Site
    Saint Louis, Missouri 63130, United States
  • Research Site
    Hackensack, New Jersey 07601, United States
  • Research Site
    New Brunswick, New Jersey 08901, United States
  • Research Site
    New York, New York 10016, United States
  • Clinical Trial Site
    Chapel Hill, North Carolina 27514, United States
  • Clinical Trial Site
    Philadelphia, Pennsylvania 19019, United States
  • Research Site
    Dallas, Texas 75390, United States
  • Research Site
    Calgary, Alberta T3B 6A8, Canada
  • Clinical Trial Site
    Edmonton, Alberta, Canada
  • Research Site
    Toronto, Ontario M5G 1X8, Canada
  • Clinical Trial Site
    Toronto, Ontario, Canada
  • Research Site
    Montreal, Quebec H3T1C5, Canada
  • Clinical Trial Site
    Regensburger Straße, Goettingen, Germany
  • Research Site
    Datteln, 45711, Germany
  • Research Site
    Munster, 48149, Germany
  • Research Site
    Catania, 95123, Italy
  • Research Site
    Gallarate, 21013, Italy
  • Clinical Trial Site
    Genoa, Italy
  • Research Site
    Genova, 16132, Italy
  • Research Site
    Rome, 00178, Italy
  • Clinical Trial Site
    Rome, Italy
  • Research Site
    Yokohama-shi, 232-0024, Japan
  • Clinical Trial Site
    Yokohama, Japan
  • Clinical Trial Site
    Seoul, Korea, Republic of
  • Clinical Trial Site
    Barcelona, Spain
  • Research Site
    Esplugues de Llobregat, 8950, Spain
  • Clinical Trial Site
    Sevilla, Spain
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Jul 2023, 42 months.

Results were first posted in Sep 2024, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2019
First posted
Nov 7, 2019
StartActual
Jan 14, 2020
Primary completionActual
Jul 31, 2023
CompletionActual
Jul 31, 2023
Results first posted
Sep 25, 2024
Last update
Sep 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04155424
Responsible party
Sponsor
First posted
Nov 7, 2019
Start date
Jan 14, 2020
Primary completion
Jul 31, 2023
Completion
Jul 31, 2023
Results posted
Sep 25, 2024
Last update
Sep 25, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eculizumab

Start the discussion